Browsing by Author "Tasdemir, D"

Now showing 1 - 4 of 4
  • No Thumbnail Available
    Item
    ANTI-ACETYLCHOLINESTERASE, ANTIPROTOZOAL AND CYTOTOXIC ACTIVITIES OF SOME TURKISH MARINE ALGAE
    Cinar, E; Taskin, E; Tasdemir, D; Ozkale, E; Grienke, U; Firsova, D
    The crude (MeOH:CHCl3) and n-hexane-soluble extracts from four brown algae (Phaeophyceae) [Petalonia fascia, Cystoseira crinita, Cystoseira foeniculacea, and Halopteris scoparia], one red alga (Rhodophyta) [Jania rubens] and three green algae (Chlorophyta) [Chaetomorpha aerea, Codium fragile subsp. fragile, and Ulva compressa] from Turkish coasts (Izmir Bay, Ayvalik and canaldcale) were assessed in vitro for their acetylcholinesterase (AChE) inhibitory activities at 200, 150, 50, 20 mu g/mL test concentration with Ellman's method. The crude extract of P. fascia possessed the highest inhibition (IC50 value of 19,22 +/- 10,47 mu g/mL) against AChE. Galanthamine HBr was used as standard drug that gave against AChE enzyme IC50 of 3.44 +/- 1.14 mu M. In the second stage, the crude, hexane-soluble, chloroform-soluble and water-methanol soluble extracts of the marine algae were observed in vitro against parasitic protozoa (Plasmodium falciparum, Trypanosoma brucei brucei, Trypanosoma cruzi ye Leishmania infantum). According to results, the most potent protozoal activities were shown by the Khex of C. crinita (IC50 value of 10,62 mu g/ml), followed by the Khex of C. fragile subsp. fragile (IC50 value of 11,89 mu g/ml). The hekzan-soluble (Khex) and chloroform-soluble (KCH) extracts gave the best results. The marine algae were also tested on MRC-5 cells (human fibroblasts) for by controlling tamoxifen. The extracts of H. scoparia, C. aerea ye C. fragile subsp. fragile showed toxicity.
  • No Thumbnail Available
    Item
    A New Network for the Advancement of Marine Biotechnology in Europe and Beyond
    Rotter, A; Bacu, A; Barbier, M; Bertoni, F; Bones, A; Cancela, ML; Carlsson, J; Carvalho, MF; Ceglowska, M; Dalay, MC; Dailianis, T; Deniz, I; Drakulovi, D; Dubnika, A; Einarsson, H; Erdogan, A; Eroldogan, OT; Ezra, D; Fazi, S; FitzGerald, RJ; Gargan, LM; Gaudêncio, SP; DeNardis, NI; Joksimovic, D; Katarzyte, M; Kotta, J; Mandalakis, M; Matijosyte, I; Mazur-Marzec, H; Massa-Gallucci, A; Mohamed, M; Nielsen, SL; Novoveská, L; Overlinge, D; Portman, ME; Pyrc, K; Rebours, C; Reinsch, T; Reyes, F; Rinkevich, B; Robbens, J; Rudovica, V; Sabotic, J; Safarik, I; Talve, S; Tasdemir, D; Schneider, XT; Thomas, OP; Torunska-Sitarz, A; Varese, GC; Vasquez, MI
    Marine organisms produce a vast diversity of metabolites with biological activities useful for humans, e.g., cytotoxic, antioxidant, anti-microbial, insecticidal, herbicidal, anticancer, pro-osteogenic and pro-regenerative, analgesic, anti-inflammatory, anticoagulant, cholesterol-lowering, nutritional, photoprotective, horticultural or other beneficial properties. These metabolites could help satisfy the increasing demand for alternative sources of nutraceuticals, pharmaceuticals, cosmeceuticals, food, feed, and novel bio-based products. In addition, marine biomass itself can serve as the source material for the production of various bulk commodities (e.g., biofuels, bioplastics, biomaterials). The sustainable exploitation of marine bio-resources and the development of biomolecules and polymers are also known as the growing field of marine biotechnology. Up to now, over 35,000 natural products have been characterized from marine organisms, but many more are yet to be uncovered, as the vast diversity of biota in the marine systems remains largely unexplored. Since marine biotechnology is still in its infancy, there is a need to create effective, operational, inclusive, sustainable, transnational and transdisciplinary networks with a serious and ambitious commitment for knowledge transfer, training provision, dissemination of best practices and identification of the emerging technological trends through science communication activities. A collaborative (net)work is today compelling to provide innovative solutions and products that can be commercialized to contribute to the circular bioeconomy. This perspective article highlights the importance of establishing such collaborative frameworks using the example of Ocean4Biotech, an Action within the European Cooperation in Science and Technology (COST) that connects all and any stakeholders with an interest in marine biotechnology in Europe and beyond.
  • No Thumbnail Available
    Item
    The Essentials of Marine Biotechnology
    Rotter, A; Barbier, M; Bertoni, F; Bones, AM; Cancela, ML; Carlsson, J; Carvalho, MF; Ceglowska, M; Chirivella-Martorell, J; Dalay, MC; Cueto, M; Dailianis, T; Deniz, I; Díaz-Marrero, AR; Drakulovic, D; Dubnika, A; Edwards, C; Einarsson, H; Erdogan, A; Eroldogan, OT; Ezra, D; Fazi, S; FitzGerald, RJ; Gargan, LM; Gaudêncio, SP; Udovic, MG; DeNardis, NI; Jónsdóttir, R; Katarzyte, M; Klun, K; Kotta, J; Ktari, L; Ljubesic, Z; Bilela, LL; Mandalakis, M; Massa-Gallucci, A; Matijosyté, I; Mazur-Marzec, H; Mehiri, M; Nielsen, SL; Novoveská, L; Overlinge, D; Perale, G; Ramasamy, P; Rebours, C; Reinsch, T; Reyes, F; Rinkevich, B; Robbens, J; Röttinger, E; Rudovica, V; Sabotid, J; Safarik, I; Talve, S; Tasdemir, D; Schneider, XT; Thomas, OP; Torunska-Sitarz, A; Varese, GC; Vasquez, M
    Coastal countries have traditionally relied on the existing marine resources (e.g., fishing, food, transport, recreation, and tourism) as well as tried to support new economic endeavors (ocean energy, desalination for water supply, and seabed mining). Modern societies and lifestyle resulted in an increased demand for dietary diversity, better health and well-being, new biomedicines, natural cosmeceuticals, environmental conservation, and sustainable energy sources. These societal needs stimulated the interest of researchers on the diverse and underexplored marine environments as promising and sustainable sources of biomolecules and biomass, and they are addressed by the emerging field of marine (blue) biotechnology. Blue biotechnology provides opportunities for a wide range of initiatives of commercial interest for the pharmaceutical, biomedical, cosmetic, nutraceutical, food, feed, agricultural, and related industries. This article synthesizes the essence, opportunities, responsibilities, and challenges encountered in marine biotechnology and outlines the attainment and valorization of directly derived or bio-inspired products from marine organisms. First, the concept of bioeconomy is introduced. Then, the diversity of marine bioresources including an overview of the most prominent marine organisms and their potential for biotechnological uses are described. This is followed by introducing methodologies for exploration of these resources and the main use case scenarios in energy, food and feed, agronomy, bioremediation and climate change, cosmeceuticals, bio-inspired materials, healthcare, and well-being sectors. The key aspects in the fields of legislation and funding are provided, with the emphasis on the importance of communication and stakeholder engagement at all levels of biotechnology development. Finally, vital overarching concepts, such as the quadruple helix and Responsible Research and Innovation principle are highlighted as important to follow within the marine biotechnology field. The authors of this review are collaborating under the European Commission-funded Cooperation in Science and Technology (COST) Action Ocean4Biotech - European transdisciplinary networking platform for marine biotechnology and focus the study on the European state of affairs.
  • No Thumbnail Available
    Item
    Mechanisms and grading of nocturia: Results from a multicentre prospective study
    Bozkurt, O; Irer, B; Kizilay, F; Erbatu, O; Sen, V; Cinar, O; Ongun, S; Cihan, A; Ozdemir, T; Tasdemir, D; Ucer, O
    Objective To identify the pathophysiological mechanisms of nocturia and the correlation of these mechanisms with nocturia severity. Methodology After approval by the local ethics committee, all patients with nocturia (>= 1 nocturnal void/night) were included and filled the Overactive Bladder questionnaire, Nocturia Quality of Life, Incontinence Questionnaire - Male Lower Urinary Tract Symptoms (male), International Consultation on Incontinence Questionnaire - Female Lower Urinary Tract Symptoms (female) and 3-day frequency-volume chart. Patients were divided into three groups according to the severity of nocturia: group 1 consisted of patients with mild (1-2 voids/night), group 2 with moderate (3-4 voids/night) and group 3 with severe nocturia (>4 voids/night). Comparative analysis was performed between groups, andP About 68.1%, 64.1% and 8.7% of the patients had nocturnal polyuria (NP), reduced bladder capacity and global polyuria, respectively. 42.7% of the patients had mixed nocturia. 6.1% of the patients did not comply with the aforementioned subtypes and defined as isolated nocturia. Regarding the severity of nocturia, 155 (41%) patients had mild, 167 (45%) patients had moderate and 57 (15%) patients had severe nocturia. Increased nocturia severity was related with decreased quality of life; higher age, urinary tract symptom scores, nocturnal urine volume, evening fluid consumption and beta-blocker medication rates. Increased nocturia severity was also associated with higher NP, global polyuria and reduced bladder capacity rates. Conclusions Nocturia mechanisms may vary between mild and moderate to severe nocturia groups according to the present study. Nocturia grading with identification of subtypes may help for better standardisation of the diagnostic and treatment approaches as well as for the design of future clinical trials.